Last reviewed · How we verify
Jacob Pontoppidan Thyssen — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Elocon 0.1 % Topical Cream | Elocon 0.1 % Topical Cream | marketed | Topical corticosteroid (Class III/IV potency) | Glucocorticoid receptor | Dermatology |
Therapeutic area mix
- Dermatology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ain Shams University · 1 shared drug class
- Fougera Pharmaceuticals Inc. · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- Peking Union Medical College Hospital · 1 shared drug class
- Pfizer · 1 shared drug class
- Wake Forest University Health Sciences · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Jacob Pontoppidan Thyssen:
- Jacob Pontoppidan Thyssen pipeline updates — RSS
- Jacob Pontoppidan Thyssen pipeline updates — Atom
- Jacob Pontoppidan Thyssen pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Jacob Pontoppidan Thyssen — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jacob-pontoppidan-thyssen. Accessed 2026-05-16.